Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-0649-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD64 Monoclonal Antibody (10.1), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The 10.1 monoclonal antibody reacts with human CD64 (FcRI), a 75 kDa type I transmembrane protein. CD64 is the high affinity receptor for IgG and is involved in antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, and regulation of cytokine production. Monocytes and macrophages express CD64, while mature granulocytes and lymphocytes are negative. Applications Reported: The 10.1 antibody has been reported for use in flow cytometric analysis. Applications Tested: This 10.1 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Antibody clone number
- 10.1
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.
Extracorporeal Hemadsorption versus Glucocorticoids during Cardiopulmonary Bypass: A Prospective, Randomized, Controlled Trial.
Patient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-γ Responsive Pathway.
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Distinct Fcγ receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibrocyte differentiation.
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
Prat M, Salon M, Allain T, Dubreuil O, Noël G, Preisser L, Jean B, Cassard L, Lemée F, Tabah-Fish I, Pipy B, Jeannin P, Prost JF, Barret JM, Coste A
Cancers 2021 Apr 13;13(8)
Cancers 2021 Apr 13;13(8)
Extracorporeal Hemadsorption versus Glucocorticoids during Cardiopulmonary Bypass: A Prospective, Randomized, Controlled Trial.
Taleska Stupica G, Sostaric M, Bozhinovska M, Rupert L, Bosnic Z, Jerin A, Ihan A, Klokocovnik T, Podbregar M
Cardiovascular therapeutics 2020;2020:7834173
Cardiovascular therapeutics 2020;2020:7834173
Patient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-γ Responsive Pathway.
Haake K, Neehus AL, Buchegger T, Kühnel MP, Blank P, Philipp F, Oleaga-Quintas C, Schulz A, Grimley M, Goethe R, Jonigk D, Kalinke U, Boisson-Dupuis S, Casanova JL, Bustamante J, Lachmann N
Cells 2020 Feb 19;9(2)
Cells 2020 Feb 19;9(2)
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Hristodorov D, Mladenov R, Brehm H, Fischer R, Barth S, Thepen T
mAbs 2014;6(5):1283-9
mAbs 2014;6(5):1283-9
Distinct Fcγ receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibrocyte differentiation.
Cox N, Pilling D, Gomer RH
Journal of immunology (Baltimore, Md. : 1950) 2014 Aug 15;193(4):1701-8
Journal of immunology (Baltimore, Md. : 1950) 2014 Aug 15;193(4):1701-8
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR
Molecular cancer therapeutics 2008 Aug;7(8):2517-27
Molecular cancer therapeutics 2008 Aug;7(8):2517-27
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with Mouse IgG1 K Isotype Control PE (Product # 12-4714-81) (blue histogram) or Anti-Human CD64 (Fc gamma Receptor 1) PE (purple histogram). Cells in the monocyte gate were used for analysis.
- Conjugate
- Yellow dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 Murlentamab opsonization of SKOV3-R2 + orients naive macrophages and reprograms TAMs towards an M1-like profile. SKOV3-R2 + ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (TAMs). ( A ) The proportion of macrophages expressing M1/M2 membrane markers (CD32, CD64, CD80, TLR2, CD163, CD36 and CD206) was determined by flow cytometry after three days of co-culture with SKOV3-R2 + cells. ( B ) The release of cytokines (IL1beta, IL12, TNFalpha, IL6, IFNgamma, IL10) and chemokines (CCL2, CCL4, CCL5, CXCL9 and CXCL10) in the culture medium was determined by AlphaLISA after three days of co-culture with SKOV3-R2 + cells. Data shown (boxplots) are the results from three different experiments (performed with three different healthy donors). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. p values were determined using one-way ANOVA analysis followed by Tukey''s multiple comparisons test.
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 CD64 and CD163 expression on monocytes, granulocytes, and lymphocytes.
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Patient mutations lead to IFN-gamma-dependent defects in the iPSC-derived macrophages. ( A ) Representative flow cytometric analysis of surface marker (HLA-DR, CD64, CD38, CD282) upregulation after IFN-gamma stimulation in healthy and patient iPSC-derived macrophages. Blue: Isotype. Pink: Surface marker. ( B ) Fold change of median fluorescent intensity (MFI) of HLA-DR, CD64, CD38 and CD282 in healthy and patient iPSC-derived macrophages ( n = 3-7, mean +- SD; each dot represents macrophages from an independent harvest and from at least three independent differentiations, Kruskal-Wallis with Dunn''s multiple comparison)) ( C ) Representative western blot analysis of STAT1 phosphorylation (pSTAT1) after stimulation with low (25 ng/mL) or high (100 ng/mL) dose of IFN-gamma. Tubulin was used as a loading control. The left side of the blot shows the protein size marker. ( D ) Densitometric analysis of STAT1 phosphorylation after IFN-gamma stimulation. Values have been normalized to loading control. ( n = 3, mean +- SD; each dot represents macrophages from an independent harvest and from at least two independent differentiations, Kruskal-Wallis with Dunn''s multiple comparison). ( E ) qRT-PCR analysis of upregulation of downstream targets IRF1, CXCL10, CCL2 and CCL4 after IFNgamma stimulation. Values have been normalized to GAPDH as housekeeping gene. ( n = 3-5, mean +- SD; each dot represents macrophages from an independent harvest and from at least two independent diffe
- Conjugate
- Yellow dye
